Profile data is unavailable for this security.
About the company
OBio Technology Shanghai Corp Ltd is a China-based company mainly engaged in the research and development and production of recombinant viruses for gene therapy. The Company is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The Company mainly conducts business in the European and American markets and the domestic market.
- Revenue in CNY (TTM)233.59m
- Net income in CNY-138.37m
- Incorporated2013
- Employees731.00
- LocationObio Technology Shanghai Corp Ltd908 Ziping RoadPudong New District, Building 19,SHANGHAI 201321ChinaCHN
- Phone+86 2 158050593
- Fax+86 2 155230588
- Websitehttps://www.obiosh.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bide Pharmatech Co Ltd | 1.10bn | 98.72m | 2.79bn | 846.00 | 28.26 | 1.37 | -- | 2.53 | 1.09 | 1.09 | 12.14 | 22.50 | 0.4585 | 1.09 | 4.76 | 1,302,686.00 | 4.06 | -- | 4.62 | -- | 38.38 | -- | 8.86 | -- | 5.29 | -- | 0.0416 | -- | 30.94 | -- | -24.94 | -- | -- | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 106.52m | -467.10m | 2.82bn | 205.00 | -- | 3.80 | -- | 26.45 | -0.7129 | -0.7129 | 0.1626 | 1.13 | 0.0839 | 0.5802 | 5.74 | 519,588.20 | -36.81 | -- | -40.09 | -- | 81.75 | -- | -438.53 | -- | 6.94 | -- | 0.2497 | -- | 88.31 | -- | -91.16 | -- | -- | -- |
| Zhejiang Shapuaisi Pharmaceutical Co Ltd | 620.60m | 7.18m | 2.85bn | 1.39k | 386.71 | 1.62 | -- | 4.59 | 0.0194 | 0.0194 | 1.67 | 4.64 | 0.2983 | 3.65 | 20.26 | 448,088.40 | 0.3351 | -0.7573 | 0.3914 | -0.8713 | 53.99 | 58.02 | 1.12 | -2.45 | 0.8316 | -- | 0.1046 | -- | 17.37 | 1.21 | -43.23 | -- | 30.36 | -- |
| Jiangsu Yahong Meditech Co Ltd | 38.05m | -420.35m | 2.95bn | 394.00 | -- | 1.28 | -- | 77.60 | -0.7375 | -0.7375 | 0.0668 | 4.03 | 0.0142 | 3.05 | 3.76 | 96,573.63 | -15.68 | -15.80 | -16.54 | -16.48 | 77.72 | 55.32 | -1,106.10 | -9,445.91 | 11.34 | -- | 0.0684 | -- | 52,594.79 | -- | -62.42 | -- | 64.28 | -- |
| Obio Technology Shanghai Corp Ltd | 233.59m | -138.37m | 3.01bn | 731.00 | -- | 1.49 | -- | 12.89 | -0.2157 | -0.2157 | 0.3624 | 3.11 | 0.0921 | 3.37 | 2.52 | 319,545.50 | -5.45 | 0.2246 | -5.99 | 0.2514 | -9.53 | 36.72 | -59.21 | 1.48 | 2.39 | -- | 0.1103 | 0.00 | -29.69 | 35.88 | -425.90 | -- | 57.00 | -- |
Data as of Jun 26 2024. Currency figures normalised to Obio Technology Shanghai Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
1.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.45m | 0.34% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 899.79k | 0.21% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 630.49k | 0.15% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 2023 | 612.00k | 0.14% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 599.99k | 0.14% |
| HSBC Jintrust Fund Management Co. Ltd.as of 31 Dec 2023 | 593.64k | 0.14% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 557.37k | 0.13% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 550.36k | 0.13% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 538.76k | 0.13% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 535.87k | 0.12% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
